Veraxa Biotech Holding AG (VRXA) Common Equity (2024 - 2025)

Veraxa Biotech Holding AG (VRXA) has reported Common Equity for 2 consecutive years, with -$123.2 million the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Common Equity fell 238.74% year-over-year to -$123.2 million; the trailing twelve-month figure through Dec 2025 stood at -$123.2 million (down 238.74% YoY), and the FY2025 full-year result was -$123.2 million, down 238.74% from the prior year.
• Common Equity fell to -$123.2 million in Q4 2025 per VRXA's latest filing, from -$36.4 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of -$36.4 million in Q4 2024 to a low of -$123.2 million in Q4 2025.